Focusing on breakthrough innovation that benefits patients
We are a pioneering, commercial-stage T cell receptor biotechnology company working to develop and commercialize a new generation of transformative medicines to address unmet needs in cancer, infectious and autoimmune diseases.
Our initial therapeutic focus is in oncology, where pivotal clinical trials are currently underway for our lead program, tebentafusp (IMCgp100), as a potential treatment for metastatic uveal melanoma, a rare form of eye cancer.
We also have a robust pipeline of programs spanning a broad range of cancer indications, as well as infectious and autoimmune diseases.
ImmTAC® molecules in action
Immunocore opens an office in the BioHealth Capital Region of Rockville, Maryland.
Immunocore Board appoints Bahija Jallal as Chief Executive Officer.
Partnership with Genentech to expand existing discovery collaboration to co-develop Immunocore's therapeutic candidate IMC-C103C.
Immunocore's second ImmTAC molecule, IMCnyeso, enters Phase I clinical trials.
Immunocore announces a collaboration and investment from the Bill and Melinda Gates Foundation to accelerate the development of ImmTAV® and ImmTAB® technology for the treatment of infectious diseases.
Immunocore announces significant laboratory expansion at Milton Park, Oxfordshire.
IMCgp100 is granted Orphan Drug Designation by the FDA for the treatment of uveal melanoma.
IMCgp100, durvalumab and tremelimumab combination trial is initiated with AstraZeneca's biologics R&D unit for treatment of metastatic cutaneous melanoma.
IMCgp100 is accepted for the EMA's adaptive pathway pilot program.
Immunocore opens a US office in Philadelphia.
Immunocore wins 'Biotech of the Year' at the Scrip awards. The Scrip Awards seek to applaud the essential role that the pharmaceutical, biotech and other allied industries play in improving healthcare.
Immunocore partners with Eli Lilly to research, co-discover and co-develop novel therapies.
Immunocore initiates a Phase II clinical trial for IMCgp100 in melanoma.
Immunocore establishes partnerships with GSK, Genentech & AstraZeneca to discover and develop novel cancer targets.
Immunocore launches its first clinical trial for IMCgp100 in malignant melanoma.
With the help of private investment, the technology is brought back in-house and two sister companies are founded; Immunocore focusing on soluble TCR technology and Adaptimmune focusing on cellular TCR therapy.
Avidex is acquired by Medigene AG.
Dr Bent Jakobsen founded Avidex as a spin-off company from his research into T cell receptors at the University of Oxford.
At Immunocore, we believe we are TCR pioneers with a passion to transform patients' lives and a goal to deliver new medicines. We will implement this bold vision by following our values.
We lead with science to benefit patients
We work together to set clear priorities and objectives aligned to the organisation’s goals, to create an environment that maximises individual contributions that will benefit patients.
We are entrepreneurial
We are drawn to opportunities to seek out key areas of improvement; we ask questions, voice opinions and take initiative to get things done.
We value diversity to drive innovation
We value and listen to all views and opinions. Our success is dependent on pushing boundaries, utilizing diverse skills and approaches to foster creative thinking.
We respect and trust each other
We respect and trust each other with good intentions and are consistent and fair as to how we treat others. We foster transparent and frequent communication.
We act with integrity
We act with integrity taking responsibility for our actions and challenge actions or decisions we believe to be wrong. We take decisions to improve the success of the organisation.